Collegium Pharmaceutical Inc (COLL) USD0.001

Sell:$29.39Buy:$29.43$0.74 (2.48%)

NASDAQ:0.87%
Market closed | Prices delayed by at least 15 minutes
Sell:$29.39
Buy:$29.43
Change:$0.74 (2.48%)
Market closed | Prices delayed by at least 15 minutes
Sell:$29.39
Buy:$29.43
Change:$0.74 (2.48%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.

Key people

Michael Thomas Heffernan
Chairman of the Board
Vikram Karnani
President, Chief Executive Officer, Director
Colleen Tupper
Chief Financial Officer, Executive Vice President
Dean J. Patras
Chief People Officer
David Dieter
Executive Vice President, General Counsel
Scott Dreyer
Executive Vice President, Chief Commercial Officer
Jane Gonnerman
Executive Vice President - Strategy and Corporate Development
Thomas B. Smith
Executive Vice President, Chief Medical Officer
Gino Santini
Independent Chairman of the Board
Rita J. Balice-Gordon
Independent Director
Garen G. Bohlin
Independent Director
John A. Fallon
Independent Director
John G. Freund
Independent Director
Click to see more

Key facts

  • EPIC
    COLL
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US19459J1043
  • Market cap
    $959.13m
  • Employees
    357
  • Shares in issue
    40.34m
  • Exchange
    NASDAQ
  • Index
    S&P 600 Small Cap, TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.